Artifical Pancreas: Medtronic in Pole Position

Medtronic says new research points to its progress toward future innovations and new systems as it looks to develop and commercialize artificial pancreas technology.

Background

Back in 2006 Medtronic introduced the world’s first integrated insulin pump and continuous glucose monitor. Nowadays teh company’s offerings include the MiniMed 640G integrated pump and continuous glucose monitor(CGM) and the Hybrid Closed Loop system, a sophisticated automatic glucose level control device that minimizes the need for patient input.

Medtronic says its MiniMed 640G is the most sophisticated integrated insulin pump and continuous glucose monitoring (CGM) system in the world, including so-called SmartGuard® technology and protective against hypoglycemia. The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit and resume insulin delivery once sensor glucose levels recover.

Medtronic’s Hybrid Closed Loop system builds on the technology of the MiniMed 640G system with a greater degree of automation meaning the patient would only need to enter their carbohydrates at mealtime and periodically calibrate the sensor. The system including a next-generation sensor is a critical next step toward a fully automated artificial pancreas.

The first clinical study results on Medtronic’s Hybrid Closed Loop system will be presented at the upcoming Advanced Technologies and Treatments for Diabetes (ATTD) 8th Annual Meeting being held at CNIT Paris La Defense from February 18-21, 2015. In addition, new data on the MiniMed 640G system is being presented, following the beginning of a global roll out of the system last month.

Company comments

“As a commercially-available product, MiniMed 640G comes closest to mimicking the functions of a healthy pancreas for people with diabetes by shutting off insulin delivery before hypoglycemia occurs,” said Francine Kaufman, M.D., chief medical officer and vice president, global medical, clinical & health affairs at Medtronic. “We are focused on continuing to make advances such as SmartGuard and Hybrid Closed Loop Technology so that people with diabetes enjoy even greater freedom and better health.”

Source: Medtronic plc

Share your thoughts

Your email address will not be published. Required fields are marked *